KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension...(results to the restated consolidated sta...),Health

years ended March 31, 2006 and 2005:

Years ended March 31,

2006

As

Previously As

Reported Adjustments Restated

Net revenues $367,618 $22 (d) $367,640

Cost of sales 123,894 41 (d) 123,935

Gross profit 243,724 (19) 243,705

Operating expenses:

Research and development 28,886 - 28,886

Purchased in-process research and -

development and transaction costs 30,441 30,441

Selling and administrative 140,395 3,042 (a)(b)(e) 143,437

Amortization of intangibles 4,784 - 4,784

Litigation - - -

Total operating expenses 204,506 3,042 207,548

Operating income 39,218 (3,061) 36,157

Other expense (income):

Interest expense 6,045 - 6,045

Interest and other income (5,737) - (5,737)

Total other expense (income) 308 - 308

Income before income taxes 38,910 (3,061) 35,849

Provision for income taxes 23,123 1,310 (a)(b)(c) 24,433

(d)(e)

Net income $15,787 $(4,371) $11,416

Earnings per share:

Basic - Class A common
'/>"/>